MX2019006260A - Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad. - Google Patents

Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.

Info

Publication number
MX2019006260A
MX2019006260A MX2019006260A MX2019006260A MX2019006260A MX 2019006260 A MX2019006260 A MX 2019006260A MX 2019006260 A MX2019006260 A MX 2019006260A MX 2019006260 A MX2019006260 A MX 2019006260A MX 2019006260 A MX2019006260 A MX 2019006260A
Authority
MX
Mexico
Prior art keywords
obesity
treatment
glp
glucagon
agonists
Prior art date
Application number
MX2019006260A
Other languages
English (en)
Inventor
Agoram Balaji
Antonsson Madeleine
Burmeister Nicole
Benthem Lambertus
Fairman David
Fritsch-Fredin Maria
Jackson Ronald
Jansson Lofmark Rasmus
Metcalfe Jacqueline
A Bednarek Maria
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2019006260A publication Critical patent/MX2019006260A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención proporciona péptidos agonistas de GLP-1/glucagón para el tratamiento de enfermedades metabólicas, por ejemplo, la obesidad.
MX2019006260A 2012-12-11 2015-05-25 Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad. MX2019006260A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11

Publications (1)

Publication Number Publication Date
MX2019006260A true MX2019006260A (es) 2019-08-14

Family

ID=50588751

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006568A MX365458B (es) 2012-12-11 2013-12-10 Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
MX2019006260A MX2019006260A (es) 2012-12-11 2015-05-25 Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015006568A MX365458B (es) 2012-12-11 2013-12-10 Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.

Country Status (26)

Country Link
US (4) US9765130B2 (es)
EP (2) EP2931745B1 (es)
JP (1) JP6490011B2 (es)
KR (1) KR102080366B1 (es)
CN (2) CN109776670A (es)
AR (1) AR093903A1 (es)
AU (3) AU2013356934C1 (es)
BR (1) BR112015012238B1 (es)
CA (1) CA2893445C (es)
CY (1) CY1121114T1 (es)
DK (2) DK2931745T3 (es)
ES (2) ES2926713T3 (es)
HK (1) HK1216179A1 (es)
HR (2) HRP20220734T1 (es)
HU (1) HUE039952T2 (es)
LT (2) LT3495380T (es)
MX (2) MX365458B (es)
PL (2) PL2931745T3 (es)
PT (2) PT2931745T (es)
RS (2) RS57899B1 (es)
RU (2) RU2018137842A (es)
SG (2) SG10201801159WA (es)
SI (2) SI3495380T1 (es)
TR (1) TR201815172T4 (es)
TW (2) TWI617574B (es)
WO (1) WO2014091316A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
MA38276B1 (fr) 2012-12-21 2018-03-30 Sanofi Sa Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) * 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN113456820B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
NZ746784A (en) 2016-03-10 2022-11-25 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
US20190388510A1 (en) * 2016-06-02 2019-12-26 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
CN111278853B (zh) * 2017-11-06 2022-06-21 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
HUE060135T2 (hu) 2018-04-05 2023-02-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok
WO2020103729A1 (zh) * 2018-11-12 2020-05-28 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
US20220249617A1 (en) 2019-05-21 2022-08-11 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
CR20220046A (es) 2019-07-01 2022-03-24 Medimmune Ltd Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
US11813312B2 (en) 2020-04-24 2023-11-14 Boehringer Ingelheim International Gmbh Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
US20240148833A1 (en) * 2022-11-03 2024-05-09 EFIL BioScience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
JP2009504681A (ja) * 2005-08-11 2009-02-05 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
ES2558155T3 (es) * 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
CA2797095A1 (en) * 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑

Also Published As

Publication number Publication date
CA2893445A1 (en) 2014-06-19
PL2931745T3 (pl) 2019-04-30
RU2671088C2 (ru) 2018-10-29
TW201427993A (zh) 2014-07-16
MX2015006568A (es) 2015-08-05
MX365458B (es) 2019-06-04
AR093903A1 (es) 2015-06-24
HUE039952T2 (hu) 2019-02-28
CN104822699B (zh) 2019-03-01
KR102080366B1 (ko) 2020-02-21
US20150307579A1 (en) 2015-10-29
EP2931745A2 (en) 2015-10-21
PT2931745T (pt) 2018-11-29
DK3495380T3 (da) 2022-06-20
RU2015127780A (ru) 2017-01-19
WO2014091316A3 (en) 2014-10-30
SG10201801159WA (en) 2018-03-28
AU2013356934B2 (en) 2017-08-17
US10556939B2 (en) 2020-02-11
TWI617574B (zh) 2018-03-11
HRP20220734T1 (hr) 2022-09-02
ES2926713T3 (es) 2022-10-27
US20170342121A1 (en) 2017-11-30
CN109776670A (zh) 2019-05-21
US11230584B2 (en) 2022-01-25
RU2018137842A (ru) 2018-12-13
US20200115431A1 (en) 2020-04-16
EP3495380A1 (en) 2019-06-12
CA2893445C (en) 2020-06-02
PT3495380T (pt) 2022-06-28
DK2931745T3 (en) 2018-12-10
ES2698329T3 (es) 2019-02-04
WO2014091316A2 (en) 2014-06-19
AU2017261505C1 (en) 2020-07-30
TW201829452A (zh) 2018-08-16
SI3495380T1 (sl) 2022-08-31
LT3495380T (lt) 2022-06-27
SI2931745T1 (sl) 2018-11-30
TWI674270B (zh) 2019-10-11
KR20150093167A (ko) 2015-08-17
CN104822699A (zh) 2015-08-05
AU2019272054A1 (en) 2020-01-02
LT2931745T (lt) 2018-11-12
BR112015012238B1 (pt) 2022-03-29
AU2013356934C1 (en) 2018-07-05
JP6490011B2 (ja) 2019-03-27
EP2931745B1 (en) 2018-08-22
SG11201503230XA (en) 2015-06-29
HRP20181678T1 (hr) 2019-03-08
RS57899B1 (sr) 2019-01-31
AU2017261505B2 (en) 2019-10-10
CY1121114T1 (el) 2019-12-11
HK1216179A1 (zh) 2016-10-21
BR112015012238A2 (es) 2017-08-15
JP2016501256A (ja) 2016-01-18
EP3495380B1 (en) 2022-03-30
PL3495380T3 (pl) 2022-08-01
RS63305B1 (sr) 2022-07-29
US9765130B2 (en) 2017-09-19
RU2018137842A3 (es) 2022-04-01
AU2013356934A1 (en) 2015-05-21
AU2017261505A1 (en) 2017-12-07
TR201815172T4 (tr) 2018-11-21
US20220098265A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
IL267284A (en) Combination therapy with a 4-bb1 (cd137)-targeted anonist
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
HK1226084A1 (zh) 用於治療糖尿病的gip和glp-1受體雙重激動劑
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX369770B (es) Compuestos agonistas triples de glucagón-glp-1-gip.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX368435B (es) Analogos del glucagon.
HRP20180641T1 (hr) Pirolidinski gpr40 modulatori za liječenje bolesti kao što je dijabetes
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
EP2970161B8 (en) Gpr120 agonists for the treatment of type ii diabetes
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
MX365403B (es) Peptidos y metodos para usarlos.
MX2016004325A (es) Nuevo derivado de un analogo de insulina.
EP3463413A4 (en) PARTIAL INSULIN RECEPTOR AGONISTS
IL248670B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
PH12018501844A1 (en) Liraglutide in cardiovascular conditions
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
MX2016007982A (es) Nuevo compuesto para el tratamiento de hipoglucemia severa.
EP3508474A4 (en) INNOVATIVE THERAPEUTIC ACTIVE SUBSTANCE FOR DIABETES
UA92304U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета
EP3093013A4 (en) Agent for treating diabetes